期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
A Randomized,Double-Blind,Placebo-Controlled Pilot Clinical Study on ColdZyme^(■) Mouth Spray against Rhinovirus-Induced Common Cold
1
作者 Mats Clarsund Marcus Fornbacke +2 位作者 Lena Uller Sebastian L. Johnston Cecilia Ahlstrom Emanuelsson 《Open Journal of Respiratory Diseases》 2017年第4期125-135,共11页
Common colds incur significant costs in terms of sick leave and personal discomfort for affected individuals. This study investigated the performance of ColdZyme? Mouth Spray (ColdZyme), a protective barrier against c... Common colds incur significant costs in terms of sick leave and personal discomfort for affected individuals. This study investigated the performance of ColdZyme? Mouth Spray (ColdZyme), a protective barrier against common cold, in rhinovirus-inoculated healthy volunteers. This randomized, doubleblind, placebo-controlled pilot study was conducted on 46 healthy volunteers inoculated with rhinovirus 16 via the nose. Subjects self-administered ColdZyme or placebo 6 times daily for 11 days. Symptoms were recorded daily in a diary. Rhinovirus 16 in nasal and oropharyngeal samples at days 0, 3, 4, 6, 7 and 10 were quantified by RT-qPCR. The primary outcome measure was the reduction in viral load in oropharyngeal samples. Rhinovirus 16 was only detected in 35 out of 46 inoculated subjects. Exploratory analysis measuring the total viral load (i.e., area under the curve (AUC)) for days 3 - 10 in successfully inoculated subjects found that ColdZyme treatment resulted in a lower total viral load in the oropharynx (p = 0.023). In subjects who experienced symptomatic common cold, irrespectively, if virus were detected, treatment with ColdZyme resulted in a reduction in the number of days with common cold symptoms from 6.5 to 3.0 days (p = 0.014) in comparison to placebo. ColdZyme reduced virus infection in the oropharynx and reduced the number of days with common cold symptoms and highlights the possible importance of the oropharynx in common cold infections. Suitable outcome measures for a feasible study on ColdZyme are total viral load in the oropharynx in subjects having detectable virus present in nasal or oropharyngeal samples. 展开更多
关键词 Common Cold RHINOVIRUS ColdZyme^(■) mouth spray
下载PDF
User Experience of ColdZyme Mouth Spray against Common Cold in Competitive Athletes
2
作者 Ulf Blom Ida Nelson 《Open Journal of Respiratory Diseases》 2018年第2期13-20,共8页
ColdZyme? Mouth Spray (ColdZyme) is intended to reduce the probability of catching a cold and/or can help shorten the duration of a cold, if used at an early stage of the infection, by forming a barrier on the pharyng... ColdZyme? Mouth Spray (ColdZyme) is intended to reduce the probability of catching a cold and/or can help shorten the duration of a cold, if used at an early stage of the infection, by forming a barrier on the pharyngeal mucous membrane. The user experience of ColdZyme on naturally occurring common cold infections was evaluated in competitive athletes training professionally or on an amateur level. Thirteen athletes completed weekly electronic surveys on occurrence of common colds, cold severity and user experience over the course of 3 months. The 13 participants reported in total 15 cold incidents with an average duration of 7.4 days. The average cold severity was 31.2 on a visual-analogue scale (VAS) ranging from 0 (mildest possible cold) to 100 (worst possible cold). The overall user satisfaction with ColdZyme was high. 81% of the reported colds were experienced to be milder and/or shorter than usual. None of the participants reported “No effect”. Out of the participants who reported absence of a cold in the previous week, 69% reported a positive answer to the question if ColdZyme had prevented them from catching a cold in the previous week. Conclusion: The present study evaluated prevention and alleviation of naturally occurring common cold in athletes, and demonstrated that ColdZyme may be an easy and practical way for competitive athletes to prevent or reduce infections of the common cold virus and corresponding unwanted absence from training and competition. Due to the lack of a comparator group, a placebo effect cannot be excluded. 展开更多
关键词 Common Cold ATHLETES ColdZyme^(■) mouth spray
下载PDF
Evaluation of ColdZyme Mouth Spray for the Protection against Common Cold in Elite Athletes to Reduce Unwanted Absence from Training and Competition
3
作者 Mats Clarsund 《Open Journal of Respiratory Diseases》 2017年第3期103-109,共7页
This study evaluated the protective effect of ColdZyme on common cold infections in elite athletes from three different sports (biathlon, ice-hockey and handball), and assessed the level of reduction in corresponding ... This study evaluated the protective effect of ColdZyme on common cold infections in elite athletes from three different sports (biathlon, ice-hockey and handball), and assessed the level of reduction in corresponding sick days. The biathlon team (n = 11) and the ice-hockey team (n = 29) significantly reduced the average number of sick days by 51% respectively 67% compared to historical data. No historical data on sick days was available for the handball team but 76% of those who experiences a cold during the study period reported little or very little impact on training and competition. Conclusion: Using ColdZyme may be an easy and practical way for elite athletes to protect themselves against the common cold and to prevent corresponding unwanted absence from training and competition. 展开更多
关键词 Common Cold ATHLETES ColdZyme^(■) mouth spray
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部